About 60% of low‑risk prostate cancer patients are opting for active surveillance — and long‑term survival remains high.

CURE highlights prostate cancer advancements from Day One of the 2026 ASCO Genitourinary Cancers Symposium.

Learn the key warning signs of prostate cancer that men often overlook. Early awareness can make all the difference.

A drug for advanced prostate cancer has shown “remarkable” results in an early-stage trial, with patients who had previously stopped being receptive to treatment finding their tumours shrinking, ...

Researchers found men who ejaculated more often had fewer prostate cancer diagnoses, pointing to a possible biological ...

Calhoun County’s health profile reflects many of Alabama’s most persistent challenges: shorter life expectancy, widespread chronic disease and uneven access to preventive care. Data from the Centers ...

Most men who are treated for prostate cancer according to modern guidelines have good survival rates and the majority of these men will die of causes other than prostate cancer. This is revealed in a ...

Global Urology Imaging Systems Market OverviewThe global urology imaging systems market is expected to register steady growth ...

Global Urology Devices Market OverviewThe global urology devices market is poised for steady expansion and is projected to grow at a CAGR of approximately 6–7% during the forecast period from 2024 to ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

Molecular profiling of tumors has been shown to improve risk stratification, and it may be useful for prostate cancer active surveillance.

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...